2. All intellectual property related to the core silicon nitride biomaterial technology will remain with Amedica, which will serve as CTL's exclusive original equipment manufacturer silicon nitride product provider.

Amedica's board chairman Sonny Bal, MD, said, "Divesting the sales organization will drive down costs, while allowing Amedica to focus on additional OEM revenue opportunities outside of spine, such as in the dental and arthroplasty markets."

3. The transaction is expected to close in the third quarter of 2018.

4. Following the transaction, CTL Medical will change its name to CTL Amedica.

The Becker's Spine Review website uses cookies to display relevant ads and to enhance your browsing experience. By continuing to use our site, you acknowledge that you have read, that you understand, and that you accept our Cookie Policy and our Privacy Policy.